Pharmacogenomics Variability of Lipid-Lowering Therapies in Familial Hypercholesterolemia
The exponential expansion of genomic data coupled with the lack of appropriate clinical categorization of the variants is posing a major challenge to conventional medications for many common and rare diseases. To narrow this gap and achieve the goals of personalized medicine, a collaborative effort...
Main Authors: | Nagham N. Hindi, Jamil Alenbawi, Georges Nemer |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-08-01
|
Series: | Journal of Personalized Medicine |
Subjects: | |
Online Access: | https://www.mdpi.com/2075-4426/11/9/877 |
Similar Items
-
Targeted Strategy in Lipid-Lowering Therapy
by: Ezgi Dayar, et al.
Published: (2022-05-01) -
Executive summary of the Hellenic Atherosclerosis Society guidelines for the diagnosis and treatment of dyslipidemias - 2023
by: N Katsiki, et al.
Published: (2024-03-01) -
The Effectiveness and Safety of Intensive Lipid-Lowering with Different Rosuvastatin-Based Regimens in Patients at High Cardiovascular Disease Risk: A Nonblind, Randomized, Controlled Trial
by: Lili Lin, et al.
Published: (2023-08-01) -
Efficacy and safety of alirocumab in patients with hypercholesterolemia not adequately controlled with non-statin lipid-lowering therapy or the lowest strength of statin: ODYSSEY NIPPON study design and rationale
by: Tamio Teramoto, et al.
Published: (2017-06-01) -
Editorial: Genetics of familial hypercholesterolemia: New insight—Volume II
by: Alpo Vuorio, et al.
Published: (2022-10-01)